The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.
FUSED AMINO PYRIDINES FOR THE TREATMENT OF BRAIN TUMORS
申请人:Cai Xiong
公开号:US20100184801A1
公开(公告)日:2010-07-22
The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.
Fused Amino Pyridines for the Treatment of Lung Cancer
申请人:Curis, Inc.
公开号:US20160317508A1
公开(公告)日:2016-11-03
The present invention relates to the use of compounds with fused amino pyridine core for the treatment of malignancies associated with brain and lung. The oral administration of compounds of the instant application results in effective brain penetration and provides for non-intrusive treatment of brain and lung tumors.
Mild and efficient synthesis of indoles and isoquinolones<i>via</i>a nickel-catalyzed Larock-type heteroannulation reaction
作者:Wei-Zhi Weng、Jian Xie、Bo Zhang
DOI:10.1039/c8ob00795k
日期:——
A simple and efficient approach for the preparation of substituted indoles and isoquinolones via a nickel-catalyzed Larock-type heteroannulation reaction is reported. This transformation employed air-stable and inexpensive Ni(dppp)Cl2 as a precatalyst and Et3N as a mild base. Moreover, the reaction occurs efficiently under mild conditions, and a wide range of substituted indoles and isoquinolones bearing
[EN] PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS<br/>[FR] DÉRIVÉS DE PURINE CONVENANT COMME INHIBITEURS DE HSP90
申请人:SLOAN KETTERING INST CANCER
公开号:WO2011044394A1
公开(公告)日:2011-04-14
The present application provides substituted purine derivatives and related compounds of the formulas shown. These com ounds are useful as inhibitors of HSP90, and hence in the treatment of related diseases. (Formulae) Z1-Z3, Xa-Xc, X2, X4, Y and R are as defined in the specification.